Key Takeaways
- Ocrevus Zunovo is a subcutaneous form of ocrelizumab, FDA-approved in 2024 to treat relapsing and primary progressive multiple sclerosis (MS).
- Each treatment can be administered in about 10 minutes, compared with several hours for traditional IV Ocrevus.
- It works by targeting CD20-positive B cells, immune cells linked to MS-related nerve damage.
- Reported benefits may include fewer relapses, slower disability progression, and a more convenient outpatient experience.
- Smart Infusion Therapy Services administers Ocrevus Zunovo across Wisconsin, and patients can talk to their provider about a referral to begin care.
What Is Ocrevus Zunovo and How Does It Help Treat Multiple Sclerosis?
Multiple sclerosis is a chronic neurological condition in which the immune system mistakenly attacks the protective covering around nerve fibers, called myelin. According to the National Multiple Sclerosis Society, nearly 1 million adults in the United States live with MS, and symptoms can include fatigue, mobility challenges, numbness, vision changes, and cognitive difficulties.
Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) is a subcutaneous biologic therapy approved by the U.S. Food and Drug Administration in 2024. It contains the same active ingredient as IV Ocrevus, which has been widely used since 2017, but is delivered through a brief injection beneath the skin instead of a multi-hour intravenous infusion.
How Does Ocrevus Zunovo Work to Manage MS Symptoms?
Ocrevus Zunovo targets CD20-positive B cells, a type of immune cell that researchers believe plays a key role in the inflammation and nerve damage seen in MS. By selectively reducing these cells, the medication may help lower relapse activity and slow the progression of disability over time. Hyaluronidase is included in the formulation to help the medication absorb efficiently through subcutaneous tissue.
What Are the Key Benefits of Ocrevus Zunovo for MS Patients?
1. Same Proven Therapy in a Quicker Format
Ocrevus Zunovo delivers the same B-cell-depleting mechanism as IV Ocrevus, which has years of clinical use behind it. The subcutaneous route can make ongoing treatment easier to fit into a patient's life without changing the underlying approach.
2. Significantly Shorter Treatment Visits
A traditional Ocrevus IV infusion typically takes several hours. Ocrevus Zunovo is administered in about 10 minutes, followed by a short monitoring period. For many patients, that means less time at the clinic and less disruption to work, school, or family.
3. Approved for Both Relapsing and Primary Progressive MS
Ocrevus has long been one of the few therapies approved for primary progressive MS, in addition to relapsing forms. Ocrevus Zunovo carries the same approvals, giving more patients access to a treatment option suited to their MS type.
4. Outpatient Experience Designed for Comfort
Because Ocrevus Zunovo is delivered as a subcutaneous injection, it can be administered in an outpatient setting with much shorter chair time than IV therapy requires. Smart Infusion Therapy Services offers private, comfortable treatment areas that many patients find calmer than a hospital infusion suite.
5. Easier Scheduling and Ongoing Coordination
Shorter visits and predictable dosing intervals make it easier to plan around daily life. Smart Infusion's care teams help coordinate insurance benefits, prior authorizations, and follow-up appointments, so ongoing therapy feels more manageable.
What Can You Expect During Ocrevus Zunovo Treatment at Smart Infusion?
Smart Infusion Therapy Services provides Ocrevus Zunovo administration at its Eau Claire, Wausau, Madison, and Onalaska clinics. Each visit is overseen by nurses experienced in neurology biologic therapies, who monitor patients throughout and after each dose. Many patients appreciate the calmer pace, personalized attention, and outpatient setting compared with hospital infusion centers.
Tips for Getting the Most From Ocrevus Zunovo Therapy
- Keep every scheduled appointment to maintain steady B-cell suppression.
- Track symptoms and any new neurological changes between visits to share with your neurologist.
- Stay current on recommended vaccinations, ideally before starting therapy, since B-cell depletion can affect immune response.
- Talk openly with your care team about side effects, lifestyle goals, and what is working.
How Can You Get Started With Ocrevus Zunovo at Smart Infusion?
Ocrevus Zunovo offers an established MS therapy in a faster, more convenient format, and the right care team can make the overall experience even smoother. Smart Infusion Therapy Services helps Wisconsin patients access neurology infusion care in a comfortable outpatient setting close to home.
If Ocrevus Zunovo may be right for you, talk to your provider about a referral to Smart Infusion Therapy Services for Ocrevus Zunovo and other neurology infusion programs.
Frequently Asked Questions
Which MS infusion therapy is best for me?
The best MS therapy depends on your disease type, prior treatments, lifestyle, and overall health. Ocrevus Zunovo is one of several options approved for both relapsing and primary progressive MS, but your neurologist is best positioned to recommend a treatment plan tailored to you.
How is Ocrevus Zunovo different from IV Ocrevus?
Both medications contain the same active ingredient, ocrelizumab. The main difference is delivery. IV Ocrevus is given as a multi-hour infusion, while Ocrevus Zunovo is a subcutaneous injection administered in about 10 minutes.
What are the most common Ocrevus Zunovo side effects?
The most commonly reported side effects include injection-site reactions, upper respiratory tract infections, and headache. Serious risks can include reactions to the injection and an increased risk of infection. Your care team will review all potential risks before starting treatment.
Are there infusion clinics near me in Wisconsin that offer Ocrevus Zunovo?
Smart Infusion Therapy Services operates infusion clinics in Eau Claire, Wausau, Madison, and Onalaska, Wisconsin, and offers neurology biologic therapies including Ocrevus Zunovo.
